Clinical effects of treatment with Tirofiban on patients with high-risk NSTE-ACS after PCI.
OBJECTIVE
To explore clinical effects of Tirofiban treatment on patients with high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) after percutaneous coronary intervention (PCI).


METHODS
107 patients with high-risk NSTE-ACS after PCI were selected and were divided into two groups. One group of 56 patients was treated with Tirofiban and a second group of 51 patients was taken as control. The occurrence conditions of creatine kinase-myoglobin (CK-MB), cardiac troponin1 (cTnI) level, hemorrhage incidents and major adverse cardiac events (MACE) incidents after treatments were compared.


RESULTS
After 24 h operation, CK-MB and cTnI level in Tirofiban group were both significantly lower than those in control group (p < 0.05), while the difference of hemorrhage incidents between two groups is of no statistical significance (p < 0.05); and the differences in overall occurrence rate of MACE incidents and the occurrence rate of angina pectoris after infarct between two groups were statistically significant (p < 0.05).


CONCLUSIONS
Tirofiban could improve the blood supply condition of hearts of patients with high-risk NSTE-ACS after emergent PCI, lower the occurrence rate of MACE incidents, and decrease the risk of hemorrhage.
Department of Cardiology, Xuzhou Central Hospital, Xuzhou, China. fuqiang@medmail.com.cn.
P
P
Wei
Y-J
YJ
Huang
X-H
XH
Zuo
Y-G
YG
Zhang
Z-Q
ZQ
Tao
C-R
CR
Qiu
Q
Q
Zhang
X-J
XJ
Yang
Q
Q
Fu
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D052279:Creatine Kinase, MB Form / Q000032:analysis; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000077466:Tirofiban; D016896:Treatment Outcome; D019210:Troponin I / Q000032:analysis; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D019210:Troponin I; D014443:Tyrosine; D052279:Creatine Kinase, MB Form; D000077466:Tirofiban